• Eurofins GeLaMed to provide test kit processing of ColoAlert^® through Germany

BERKELEY, Calif. and MAINZ, Germany, May 03, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it has added Eurofins GeLaMed to its network of lab partners offering PCR test kit processing of ColoAlert^®, its flagship product that is a highly efficacious and easy to use at-home screening test for colorectal cancer (CRC). Eurofins GeLaMed has four locations throughout Germany and is part of Eurofins Scientific, an international laboratory group with more than 61,000 employees in 61 countries, conducting more than 450 million tests annually.

Eurofins GeLaMed provides its customers with a wide range of high-quality services across eleven medical departments covering advanced and modern diagnostic options in human genetics, medical microbiology, laboratory medicine and molecular diagnostics. According to GeLaMed, its almost 500 employees process more than 15,000 orders per working day and offer more than 2,000 different analytical methods from their laboratory medicine and microbiology portfolios under the direction of medical specialists.

Marcus Cholewa, Business Line Director Clinical Diagnostics DACH at Eurofins, expressed excitement about the collaboration between Mainz Biomed and Eurofins GeLaMed, stating that Eurofins is always dedicated to delivering excellent customer service, quality, and advanced analytical solutions, as well as the most comprehensive range of testing methods. He also mentioned that Eurofins has a history of introducing innovative and high-value diagnostic testing products, and that by collaborating, they could assist in identifying colorectal cancer (CRC) and provide patients with personalized information to effectively manage their health.

Under the terms of the agreement, Eurofins GeLaMed will offer ColoAlert at its testing sites and Mainz Biomed will assist with physician and patient education programs as part of the product launch, highlighting the importance of early screening for the detection and prevention of CRC.

About ColoAlert

ColoAlert^®, Mainz Biomed’s flagship product, delivers high sensitivity and specificity in a user-friendly, at-home colorectal cancer (CRC) screening kit. This non-invasive test can be indicative of tumors as determined by analyzing tumor DNA, offering better early detection than fecal occult blood tests (FOBT). Based on PCR-technology, ColoAlert detects more cases of colorectal cancer than other stool tests and allows for an earlier diagnosis (Gies et al., 2018). The product is commercially available in select EU countries through a network of leading independent laboratories, corporate health programs and via direct sales. To receive marketing approval in the US, ColoAlert will be evaluated in the FDA-registration trial ‘ReconAAsense.’ Once approved in the US, the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.

About Colorectal Cancer

Colorectal cancer (CRC) is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund International. The US Preventive Services Task Force recommends that screening with stool DNA tests such as ColoAlert should be conducted once every three years starting at age 45. Each year in the US, 16.6 million colonoscopies are performed. However, roughly one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a $4.0B+ total market opportunity in the US.

About Mainz Biomed NV

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.

For media inquiries, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.

In Europe:

MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
This email address is being protected from spambots. You need JavaScript enabled to view it.

In the US:

Spectrum Science
Melissa Laverty/Valerie Enes
+1 540 272 6465
This email address is being protected from spambots. You need JavaScript enabled to view it.

For investor inquiries, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on May 5, 2022. The Company’s SEC filings are available publicly on the SEC’s website at sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.